ATE302266T1 - Verfahren zur kontrollierung der sialylierung von durch säugetierzellkulturhergestellten protein - Google Patents

Verfahren zur kontrollierung der sialylierung von durch säugetierzellkulturhergestellten protein

Info

Publication number
ATE302266T1
ATE302266T1 AT96918251T AT96918251T ATE302266T1 AT E302266 T1 ATE302266 T1 AT E302266T1 AT 96918251 T AT96918251 T AT 96918251T AT 96918251 T AT96918251 T AT 96918251T AT E302266 T1 ATE302266 T1 AT E302266T1
Authority
AT
Austria
Prior art keywords
cell culture
protein produced
mammal cell
sialylation
controlling
Prior art date
Application number
AT96918251T
Other languages
English (en)
Inventor
Tina Etcheverry
Thomas Ryll
Werner Lesslauer
Thomas Schreitmuller
Wolfgang Richter
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23863440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE302266(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE302266T1 publication Critical patent/ATE302266T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96918251T 1995-06-06 1996-06-06 Verfahren zur kontrollierung der sialylierung von durch säugetierzellkulturhergestellten protein ATE302266T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/469,348 US5705364A (en) 1995-06-06 1995-06-06 Mammalian cell culture process
PCT/US1996/009284 WO1996039488A1 (en) 1995-06-06 1996-06-06 Process for controlling sialylation of proteins produced by mammalian cell culture

Publications (1)

Publication Number Publication Date
ATE302266T1 true ATE302266T1 (de) 2005-09-15

Family

ID=23863440

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05017434T ATE425245T2 (de) 1995-06-06 1996-06-06 Verfahren zur kontrollierung der sialylierung von durch säugetierzellkultur hergestellten proteinen
AT96918251T ATE302266T1 (de) 1995-06-06 1996-06-06 Verfahren zur kontrollierung der sialylierung von durch säugetierzellkulturhergestellten protein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05017434T ATE425245T2 (de) 1995-06-06 1996-06-06 Verfahren zur kontrollierung der sialylierung von durch säugetierzellkultur hergestellten proteinen

Country Status (36)

Country Link
US (1) US5705364A (de)
EP (2) EP0832189B2 (de)
JP (2) JPH11507523A (de)
KR (1) KR100496356B1 (de)
CN (1) CN1166772C (de)
AR (2) AR004940A1 (de)
AT (2) ATE425245T2 (de)
AU (1) AU717847B2 (de)
BG (1) BG63213B1 (de)
BR (1) BR9609150A (de)
CA (1) CA2220684C (de)
CZ (1) CZ293719B6 (de)
DE (2) DE69635076T3 (de)
DK (2) DK1609853T4 (de)
EA (1) EA001215B1 (de)
ES (2) ES2248812T5 (de)
GE (1) GEP20012519B (de)
HK (2) HK1017903A1 (de)
HU (1) HU226420B1 (de)
IL (1) IL122398A (de)
IS (1) IS2614B (de)
MY (1) MY113496A (de)
NO (1) NO322276B1 (de)
NZ (1) NZ310202A (de)
OA (1) OA10753A (de)
PL (1) PL185484B1 (de)
PT (1) PT1609853E (de)
RO (1) RO120267B1 (de)
SA (1) SA96170351B1 (de)
SI (2) SI0832189T2 (de)
SK (1) SK282658B6 (de)
TR (1) TR199701543T1 (de)
TW (2) TW426734B (de)
UA (1) UA47428C2 (de)
WO (1) WO1996039488A1 (de)
ZA (1) ZA964776B (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5705364A (en) † 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
KR20000010825A (ko) * 1996-05-08 2000-02-25 프리돌린 클라우스너, 롤란드 비. 보레르 종양괴사인자 수용체-면역 글로불린 융합 단백질을 사용한 천식의 치료방법
ATE309350T1 (de) * 1997-12-03 2005-11-15 Roche Diagnostics Gmbh Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
US6140445A (en) * 1998-04-17 2000-10-31 Crompton Corporation Silane functional oligomer
ATE314485T1 (de) * 1998-05-29 2006-01-15 Genentech Inc Zellkulturverfahren für die produktion von glycoproteinen
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
GB9828624D0 (en) * 1998-12-23 1999-02-17 Glaxo Group Ltd Production of proteins
KR100475417B1 (ko) * 1998-12-30 2005-07-18 씨제이 주식회사 시알산 함량이 높은 재조합 당단백질의 제조방법
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
EP1171615B1 (de) 1999-04-26 2006-12-13 Genentech, Inc. Zellenzuchtverfahren für glycoproteine
US6261805B1 (en) * 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
KR100394474B1 (ko) * 1999-12-18 2003-08-09 동아제약 주식회사 동물세포에서 재조합 당단백질의 연속식 대량생산 방법
ES2256234T3 (es) * 2000-05-16 2006-07-16 Lipoxen Technologies Limited Derivatizacion de proteinas en solucion acuosa.
EP1298217A4 (de) * 2000-07-05 2004-09-08 Mitsubishi Pharma Corp Verfahren zur Herstellung eines Glykoproteins
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
CA2447791A1 (en) * 2001-06-13 2002-12-19 Neslihan Delacruz Methods of culturing animal cells and polypeptide production in animal cells
ES2557741T3 (es) 2002-03-27 2016-01-28 Immunex Corporation Procedimientos para incrementar la producción de polipéptidos
US20030190710A1 (en) * 2002-03-28 2003-10-09 Devries Ruth L. Control of glycoforms in IgG
US6974681B1 (en) 2002-08-23 2005-12-13 Immunex Corporation Cell culture performance with vanadate
US6924124B1 (en) * 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US7067279B1 (en) * 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
ES2347239T3 (es) * 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
AU2003303394B2 (en) * 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
EP1620457A2 (de) * 2003-04-25 2006-02-01 Immunex Corporation Induktoren der expression rekombinanter proteine
EP2298898B1 (de) 2003-10-24 2012-12-26 Selexis S.A. Gentransfer und Expression mit hoher Effizienz in Säugerzellen mittels eines Mehrfachtransfektionsverfahrens von Matrixbindungsbereichsequenzen
WO2005063813A2 (en) * 2003-12-23 2005-07-14 Applied Research Systems Ars Holding N.V. Process for the production of tumor necrosis factor-binding proteins
EP1709185A1 (de) * 2003-12-31 2006-10-11 Samyang Genex Corporation Verfahren zur massenherstellung sekundärer metaboliten in pflanzenzellkulturen durch behandlung einer alkansäure oder eines salzes davon
WO2005080585A1 (en) * 2004-02-13 2005-09-01 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
CA2607663C (en) * 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
AU2006254217A1 (en) * 2005-06-03 2006-12-07 Biovitrum Ab (Publ) Process for cultivating animal cells comprising the feeding of plant-derived peptones
KR100670105B1 (ko) 2005-06-29 2007-01-17 주식회사 셀트리온 콩가수분해물의 저분자량 분획을 이용하여 시알산 함량이증가된 에리스로포이에틴을 생산하는 방법 및 그에 의하여생산된 시알산 함량이 증가된 에리스로포이에틴
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
PE20080556A1 (es) 2005-12-20 2008-06-13 Bristol Myers Squibb Co Composicion que comprende una poblacion aislada de moleculas ctla4-ig a partir de un medio de cultivo liquido y metodos para su obtencion
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US20070184065A1 (en) * 2006-01-26 2007-08-09 Jan Holgersson Compositions and Methods for Inhibiting Viral Adhesion
EP3456351A1 (de) 2006-04-05 2019-03-20 The Rockefeller University Polypeptide mit verbesserten entzündungshemmenden und verminderten zytotoxischen eigenschaften und verfahren im zusammenhang damit
ES2668212T3 (es) 2006-07-13 2018-05-17 Wyeth Llc Producción de factor de coagulación IX con patrón de glucosilación mejorado
SG10201510384UA (en) 2006-09-13 2016-01-28 Abbvie Inc Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US20080145893A1 (en) * 2006-09-17 2008-06-19 Excellegene Sa Method for producing a recombinant protein at high specific productivity, high batch yield and high volumetric yield by means of transient transfection
AU2007317755A1 (en) * 2006-10-27 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2008069244A1 (ja) * 2006-12-05 2008-06-12 Kyowa Hakko Kogyo Co., Ltd. 糖蛋白質組成物の製造方法
WO2008128228A1 (en) * 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Methods related to cell surface glycosylation
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090023186A1 (en) * 2007-07-22 2009-01-22 Excellgene Sa Use of valproic acid for enhancing production of recombinant proteins in mammalian cells
US20090042253A1 (en) * 2007-08-09 2009-02-12 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
FI4269578T3 (fi) 2008-03-06 2024-06-07 Halozyme Inc Liukoisen hyaluronidaasin suurimittainen tuotanto
ES2517603T3 (es) * 2008-04-07 2014-11-03 Bayer Healthcare, Llc Procedimientos de producción recombinante de glucoproteínas
EP2279410B1 (de) 2008-04-22 2015-11-11 The Rockefeller University Verfahren zur identifizierung entzündungshemmender verbindungen
CA2734922C (en) 2008-09-15 2020-01-14 Laetitia Malphettes Compositions comprising polynucleotides comprising hybrid osmo-responsive transcriptional regulatory elements and methods for producing a protein under conditions of hyperosmolarity
WO2010048192A2 (en) 2008-10-20 2010-04-29 Abbott Laboratories Viral inactivation during purification of antibodies
MX2011004200A (es) * 2008-10-20 2011-05-24 Abbott Lab Aislamento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.
NZ593641A (en) 2008-12-09 2013-01-25 Halozyme Inc Extended soluble ph20 polypeptides and uses thereof
EP2403523A1 (de) * 2009-03-06 2012-01-11 Halozyme, Inc. Temperaturempfindliche mutanten von matrix metalloprotease 1 und ihre verwendungen
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
SI3202785T1 (sl) 2009-10-26 2024-08-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo glikoziliranega imunoglobulina
EP3255153A1 (de) 2009-11-17 2017-12-13 E. R. Squibb & Sons, L.L.C. Verfahren für erhöhte proteinproduktion
IN2012DN05169A (de) * 2009-12-02 2015-10-23 Acceleron Pharma Inc
US8974780B2 (en) * 2010-02-24 2015-03-10 Zymenex A/S Process for production and purification of recombinant lysosomal alpha-mannosidase
EP2610338A4 (de) 2010-08-02 2015-03-25 Kyowa Hakko Kirin Co Ltd Verfahren zur herstellung einer substanz
WO2012122625A1 (en) 2011-03-14 2012-09-20 National Research Council Of Canada Method of viral production in cells
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
ES2560470T3 (es) 2011-04-29 2016-02-19 Biocon Research Limited Un método para reducir la heterogeneidad de anticuerpos y un proceso de producción de dichos anticuerpos
EP2718328A4 (de) 2011-06-08 2014-12-24 Acceleron Pharma Inc Zusammensetzungen und verfahren zur erhöhung der halbwertszeit von serum
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
CN102839157A (zh) * 2012-07-12 2012-12-26 扬州大学 稳定共表达hST3GalIV和β1-4GalT1的MDCK细胞系及构建方法和应用
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (pt) 2012-09-02 2017-03-21 Abbvie Inc método para controlar a heterogeneidade de proteínas
NO2760138T3 (de) 2012-10-01 2018-08-04
EP2906683B1 (de) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Säugerzellkulturverfahren zur proteinproduktion
US20140106405A1 (en) * 2012-10-15 2014-04-17 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
RU2674996C2 (ru) 2013-07-04 2018-12-14 Ф. Хоффманн-Ля Рош Аг Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки
IN2013MU02285A (de) 2013-07-06 2015-06-19 Cadila Healthcare Ltd
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
BR112016017660B1 (pt) * 2014-02-27 2022-04-19 F. Hoffmann-La Roche Ag Método para a produção de uma glicoproteína recombinante
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
CN106536746A (zh) * 2014-06-03 2017-03-22 鲁宾有限公司 用于生产蛋白的细胞培养方法
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
KR102007930B1 (ko) * 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
US20180334493A1 (en) 2015-11-19 2018-11-22 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
BR112018013501B1 (pt) * 2015-12-29 2022-12-20 N.V. Nutricia Uso de um ingrediente fermentado e oligossacarídeo não digerível
JP7471220B2 (ja) * 2017-11-30 2024-04-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 哺乳動物細胞の培養方法
CN113015805A (zh) 2018-11-13 2021-06-22 詹森生物科技公司 抗cd38抗体产生期间的痕量金属的控制
IL302538A (en) 2019-12-06 2023-07-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
MX2023002417A (es) 2020-08-31 2023-03-22 Regeneron Pharma Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina.
US12031151B2 (en) 2021-01-20 2024-07-09 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
IL311248A (en) 2021-10-07 2024-05-01 Regeneron Pharma PH meter calibration and repair
WO2023059800A2 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
WO2023167863A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3926723A (en) 1974-08-08 1975-12-16 Massachusetts Inst Technology Method of controllably releasing glucose to a cell culture medium
JPS5938488B2 (ja) 1979-05-07 1984-09-17 株式会社東芝 空気調和機
IL69027A (en) * 1982-06-21 1988-08-31 Wellcome Found Process for the production of interferon
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4724206A (en) * 1984-02-13 1988-02-09 Damon Biotech, Inc. Protein production using hypertonic media
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
JPH0639919B2 (ja) 1985-08-29 1994-05-25 トヨタ自動車株式会社 過給機付き内燃機関の異常判別装置
GB8606386D0 (en) * 1986-03-14 1986-04-23 Celltech Ltd Production of protein
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1988001643A1 (en) 1986-08-29 1988-03-10 Endotronics, Inc. Method of culturing cells
JPH01257492A (ja) * 1987-03-05 1989-10-13 Green Cross Corp:The 異種蛋白質の生産増強方法
IL87737A (en) * 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
JPH066054B2 (ja) 1987-10-15 1994-01-26 帝人株式会社 動物細胞の培養方法
CA1312030C (en) * 1987-11-18 1992-12-29 Brian Maiorella Method to increase antibody titer
US5151359A (en) * 1988-05-19 1992-09-29 Mitsui Toatsu Chemicals Incorporated Method for producing of human tissue type plasminogen activator
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
KR0132666B1 (en) * 1989-03-14 1998-04-14 Hitachi Kk Method for controlling cultivation conditions for animal cells
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5096816A (en) * 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) * 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
WO1993010260A1 (en) * 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2123593C (en) * 1992-09-15 2000-03-14 Craig A. Smith Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
JP3523293B2 (ja) † 1993-07-19 2004-04-26 住友製薬株式会社 インターフェロンの産生増強法
US5705364A (en) † 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP5515221B2 (ja) † 2008-01-28 2014-06-11 日油株式会社 ポリオキシエチレンソルビタン脂肪酸エステルの製造方法

Also Published As

Publication number Publication date
JPH11507523A (ja) 1999-07-06
IS2614B (is) 2010-04-15
SI1609853T1 (sl) 2009-08-31
DE69637867D1 (de) 2009-04-23
HK1017903A1 (en) 1999-12-03
ZA964776B (en) 1997-12-08
BG102101A (en) 1998-07-31
PL323737A1 (en) 1998-04-14
CA2220684A1 (en) 1996-12-12
EP0832189B2 (de) 2008-07-09
ES2248812T3 (es) 2006-03-16
ES2324046T3 (es) 2009-07-29
HK1087151A1 (en) 2006-10-06
NO322276B1 (no) 2006-09-04
TW516962B (en) 2003-01-11
DE69635076T3 (de) 2009-01-15
CA2220684C (en) 2002-11-12
JP4348376B2 (ja) 2009-10-21
PT1609853E (pt) 2009-06-09
CZ390997A3 (cs) 1998-06-17
US5705364A (en) 1998-01-06
EA199700364A1 (ru) 1998-04-30
EP0832189A1 (de) 1998-04-01
ES2324046T5 (es) 2020-09-14
ES2248812T5 (es) 2008-12-16
DK0832189T3 (da) 2005-11-21
HUP9900920A3 (en) 2001-06-28
OA10753A (en) 2002-12-11
NO975674D0 (no) 1997-12-05
ATE425245T2 (de) 2009-03-15
HU226420B1 (en) 2008-12-29
EA001215B1 (ru) 2000-12-25
DK1609853T4 (da) 2020-04-06
DE69635076T2 (de) 2006-06-01
TR199701543T1 (xx) 1998-05-21
NO975674L (no) 1998-02-06
DK1609853T3 (da) 2009-06-02
EP1609853A1 (de) 2005-12-28
PL185484B1 (pl) 2003-05-30
KR19990022473A (ko) 1999-03-25
TW426734B (en) 2001-03-21
MY113496A (en) 2002-03-30
SI0832189T1 (sl) 2006-02-28
IL122398A0 (en) 1998-06-15
DK0832189T4 (da) 2008-10-27
UA47428C2 (uk) 2002-07-15
CN1166772C (zh) 2004-09-15
SK167097A3 (en) 1998-07-08
SI0832189T2 (sl) 2008-12-31
GEP20012519B (en) 2001-08-27
EP1609853B1 (de) 2009-03-11
NZ310202A (en) 1999-10-28
AR011439A2 (es) 2000-08-16
RO120267B1 (ro) 2005-11-30
DE69635076D1 (de) 2005-09-22
EP0832189B1 (de) 2005-08-17
BG63213B1 (bg) 2001-06-29
AU717847B2 (en) 2000-04-06
BR9609150A (pt) 1999-02-23
CZ293719B6 (cs) 2004-07-14
SI1609853T2 (sl) 2020-07-31
IL122398A (en) 2001-12-23
HUP9900920A2 (hu) 1999-07-28
CN1186514A (zh) 1998-07-01
KR100496356B1 (ko) 2005-11-25
MX9709452A (es) 1998-06-30
EP1609853B2 (de) 2020-01-22
IS4626A (is) 1997-12-03
JP2007190024A (ja) 2007-08-02
AR004940A1 (es) 1999-04-07
SK282658B6 (sk) 2002-11-06
SA96170351B1 (ar) 2006-07-04
WO1996039488A1 (en) 1996-12-12
AU6095296A (en) 1996-12-24

Similar Documents

Publication Publication Date Title
ATE302266T1 (de) Verfahren zur kontrollierung der sialylierung von durch säugetierzellkulturhergestellten protein
DE69333823D1 (de) Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
DE69632887D1 (de) Verfahren zur zweckmässige Herstellung von Transglutaminase durch DNA-Rekombination
DE59608743D1 (de) Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte-fermentation
DE69636831D1 (de) Verfahren zur herstellung heteromultimerer polypeptide
ATE212970T1 (de) Verfahren zur herstellung von essigsäure durch carbonylierung
DE69123822D1 (de) Verfahren zur funktionsüberwachung von brennstoffzellen
DE19681532T1 (de) Verfahren zur Herstellung von L-Glutaminsäure durch Fermentation
DE69516188D1 (de) Verfahren zur herstellung von therephthalsäure
ATE318146T1 (de) Verfahren zur aufkonzentrierung von antikörperlösungen
DE69603255D1 (de) Verfahren zur modifizierung von oberflächen
DE69305706D1 (de) Verfahren zur Verbrennungsregelung
ATE131876T1 (de) Verfahren zur herstellung von proteinen durch verwendung von cks-fusionsproteinen
DE69331269D1 (de) Verfahren zur herstellung von antikörpern
DE59702539D1 (de) Verfahren zur reinigung von roh-acrylsäure durch kristallisation
DE69534886D1 (de) Verfahren zur Isolierung von Zellkomponenten
DE69426520D1 (de) Neues verfahren zur herstellung von ergothionein
DE69316385D1 (de) Verfahren zur reinigung von acetanhydrid
DE69331354D1 (de) Verfahren zur Zellenflusssteuerung
ATE204120T1 (de) Verfahren zur vermehrung von pflanzenmaterial
DE69304295D1 (de) Verfahren zur herstellung von 2-hydroxy-4-methylthiobutansäure
DE69802515D1 (de) Verfahren zur anreicherung von rohsalz
DE69611430D1 (de) Verfahren zur reinigung von roher naphthalendicarbonsäure
ATE207898T1 (de) Verfahren zur herstellung von acryl-piperidin- carbinolen
DE59607103D1 (de) Verfahren zur gewinnung von 2-hydroxy-4-methylthiobuttersäure (mha)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0832189

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 0832189

Country of ref document: EP